Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis

Cleveland Clinic Journal of Medicine

Volumn 69, Issue SUPPL. 1, 2002, Pages

  Bingham III, Clifton O ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; ETORICOXIB; KETOROLAC; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PROSTACYCLIN; PROSTAGLANDIN; PROSTANOID; ROFECOXIB; SULFONAMIDE; THROMBOXANE; VALDECOXIB; PROSTAGLANDIN SYNTHASE INHIBITOR;

ANKYLOSING SPONDYLITIS; ARTHROPATHY; ASTHMA; CLINICAL TRIAL; DIGESTIVE SYSTEM INJURY; DISABILITY; DRUG EFFICACY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; GOUT; HUMAN; KIDNEY INJURY; OSTEOARTHRITIS; REVIEW; RHEUMATOID ARTHRITIS; UNITED STATES; DRUG EFFECT; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; NEEDLE BIOPSY; PATHOLOGY; PROGNOSIS; SYNOVIUM; TREATMENT OUTCOME;

ARTHRITIS, RHEUMATOID; BIOPSY, NEEDLE; CLINICAL TRIALS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; OSTEOARTHRITIS; PROGNOSIS; SYNOVIAL MEMBRANE; TREATMENT OUTCOME;

EID: 18344408145     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.69.suppl_1.si5     Document Type: Review

References (58)

1. Sangha O. Epidemiology of rheumatic diseases. Rheumatology (Oxford) 2000; 39(suppl 2):3-12.
2. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971; 231:232-235.
3. Crofford LJ, Lipsky PE, Brooks P, Abramson SB, Simon LS, van de Putte LBA. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors. Arthritis Rheum 2000; 43:4-13.
4. FitzGerald GA, Loll P. COX in a crystal ball: current status and future promise of prostaglandin research. J Clin Invest 2001; 107:1335-1337.
5. Riendeau D, Percival MD, Brideau C, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001; 296:558-566.
6. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343:1520-1528.
7. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: The CLASS study: a randomized controlled trial. JAMA 2000; 284:1247-1255.
8. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001; 44:1237-1247.
9. Schnitzer TJ. Osteoarthritis (Degenerative Joint Disease). In: Goldman L, Bennett JC, editors. Cecil Textbook of Medicine. Philadelphia: W.B. Saunders, 1996:1550-1554.
10. Abramson SB. The role of COX-2 produced by cartilage in arthritis. Osteoarthritis Cartilage 1999; 7:380-381.
11. Hamerman D. The biology of osteoarthritis. N Engl J Med 1989; 320:1322-1330.
12. Amin AR, Attur M, Patel RN, et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. J Clin Invest 1997; 99:1231-1237.
13. Raisz LG. Prostaglandins and bone: physiology and pathophysiology. Osteoarthritis Cartilage 1999; 7:419-421.
14. Ling SM, Bathon JM. Osteoarthritis in older adults. J Am Geriatr Soc 1998; 46:216-225.
15. Arnett FC. Rheumatoid arthritis. In: Goldman L, Bennett JC, editors. Cecil Textbook of Medicine. Philadelphia: WB Saunders, 1996:1492-1499.
16. Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 2000; 43:2143-2151.
17. Robinson DR, Tashjian AH Jr, Levine L. Prostaglandin-stimulated bone resorption by rheumatoid synovia. A possible mechanism for bone destruction in rheumatoid arthritis. J Clin Invest 1975; 56:1181-1188.
18. Inoue H, Takamori M, Nagata N, et al. An investigation of cell proliferation and soluble mediators induced by interleukin 1β in human synovial fibroblasts: comparative response in osteoarthritis and rheumatoid arthritis. Inflamm Res 2001; 50:65-72.
19. Goldring MB. The role of the chondrocyte in osteoarthritis. Arthritis Rheum 2000; 43:1916-1926.
20. Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105:315-383.
21. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from nonaspirin nonsteroidal antiinflammatory drugs. Gastroenterology 1993; 105:1078-1088.
22. Henry D, Lim LL-Y, García Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312:1563-1566.
23. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to use of nonsteroidal antiinflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115:787-796.
24. Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med 1991; 115:195-200.
25. Langman MJS, Weil J, Wainwright P, et al. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994; 343:1075-1078.
26. García Rodriguez LA, Cattaruzzi C, Troncon MG, Agostinis L. Risk of hospitalization for upper gastrointestinal tract bleeding associated with ketorolac, other nonsteroidal anti-inflammatory drugs, calcium antagonists, and other antihypertensive drugs. Arch Intern Med 1998; 158:33-39.
27. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340:1888-1899.
28. Brooks P, Emery P, Evans JF, et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology (Oxford) 1999; 38:779-788.
29. Smith WL, DeWitt DL, Garavito RM. Cyclooxygenases: structural, cellular, and molecular biology. Annu Rev Biochem 2000; 69:145-182.
30. Crofford LJ, Wilder RL, Ristimaki AP, et al. Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids. J Clin Invest 1994; 93:1095-1101.
31. Klein-Nulend J, Burger EH, Semeins CM, Raisz LG, Pilbeam CC. Pulsating fluid flow stimulates prostaglandin release and inducible prostaglandin G/H synthase mRNA expression in primary mouse bone cells. J Bone Miner Res 1997; 12:45-51.
32. Tsubouchi Y, Sano H, Yamada R, et al. Preferential inhibition of cyclooxygenase-2 by meloxicam in human rheumatoid synoviocytes. Eur J Pharmacol 2000; 395:255-263.
33. 2 up-regulates cyclooxygenase-2 and amplifies cytokine-mediated prostaglandin production in human rheumatoid synoviocytes. J Immunol 2000; 165:2790-2797.
34. Anderson GD, Hauser SD, McGarity KL, Bremer ME, Isakson PC, Gregory SA. Selective inhibition of cyclooxygenase (COX)-2 reverses inflammation and expression of COX-2 and interleukin 6 in rat adjuvant arthritis. J Clin Invest 1996; 97:2672-2679.
35. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. Proc Natl Acad Sci USA 1994; 91:12013-12017.
36. Lee YH, Choi SJ, Kim A, Kim CH, Ji JD, Song GG. Expression of cyclooxygenase-1 and -2 in rheumatoid arthritis synovium. J Korean Med Sci 2000; 15:88-92.
37. Siegle I, Klein T, Backman JT, Saal JG, Nüsing RM, Fritz P. Expression of cyclooxygenase 1 and cyclooxygenase 2 in human synovial tissue. Differential elevation of cyclooxygenase 2 in inflammatory joint diseases. Arthritis Rheum 1998; 41:122-129.
38. Kang RY, Freire-Moar J, Sigal E, Chu CQ. Expression of cyclooxygenase-2 in human and an animal model of rheumatoid arthritis. Br J Rheumatol 1996; 35:711-718.
39. Salvemini D. Regulation of cyclooxygenase enzymes by nitric oxide. Cell Mol Life Sci 1997; 53:576-582.
40. Amin AR, Abramson SB. The role of nitric oxide in articular cartilage breakdown in osteoarthritis. Curr Opin Rheumatol 1998; 10:263-268.
41. 2 via the induction of cyclooxygenase-2. J Immunol 2000; 165:3402-3410.
42. Kurumbail RG, Stevens AM, Gierse JK, et al. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. Nature 1996; 384:644-648.
43. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. Arthritis Rheum 2000; 43:1905-1915.
44. Van Hecken A, Schwartz JI, Depré M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000; 40:1109-1120.
45. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2 [erratum appears in Proc Natl Acad Sci U S A 1999 May 11;96:5890]. Proc Natl Acad Sci U S A 1999; 96:272-277.
46. Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M. Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001; 31:219-225.
47. Stevenson DD, Simon RA. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001; 108:47-51.
48. Dahlén B, Szczeklik A, Murray JJ for The Celecoxib in Aspirin-Intolerant Asthma Study Group. Celecoxib in patients with asthma and aspirin intolerance. N Engl J Med 2001; 344:142.
49. Kelkar PS, Butterfield JH, Teaford HG. Urticaria and angioedema from cyclooxygenase-2 inhibitors. J Rheumatol 2001; 28:2553-2554.
50. Sanchez Borges M, Capriles-Hulett A, Caballero-Fonseca F, Perez CR. Tolerability to new COX-2 inhibitors in NSAID-sensitive patients with cutaneous reactions. Ann Allergy Asthma Immunol 2001; 87:201-204.
51. Asero R. Tolerability of rofecoxib. Allergy 2001; 56:916-917.
52. Levy MB, Fink JN. Anaphylaxis to celecoxib. Ann Allergy Asthma Immunol 2001; 87:72-73.
53. Patterson R, Bello AE, Lefkowith J. Immunologic tolerability profile of celecoxib. Clin Ther 1999; 21:2065-2079.
54. Lipsky PE, Brooks P, Crofford L, et al. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med 2000; 160:913-920.
55. Patrono C, Patrignani P, García Rodriguez LA. Cyclooxygenase- selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. J Clin Invest 2001; 108:7-13.
56. Hennan JK, Huang JB, Barrett TD, et al. Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 2001; 104:820-825.
57. Catella-Lawson F, McAdam B, Morrison BW, et al. Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther 1999; 289:735-741.
58. Perazella MA, Tray K. Selective cyclooxygenase-2 inhibitors: a pattern of nephrotoxicity similar to traditional nonsteroidal antiinflammatory drugs. Am J Med 2001; 111:64-67.